Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 04 Sep 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ibrutinib (Primary)
Indications B-cell leukaemia; B-cell lymphoma; Bladder cancer; Chronic lymphocytic leukaemia; Colon cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Gastric cancer; Graft-versus-host disease; Head and neck cancer; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Pancreatic cancer; Renal cancer; Solid tumours; Waldenstrom's macroglobulinaemia
Focus Therapeutic Use
Sponsors Pharmacyclics Switzerland

17 Jun 2024 Planned End Date changed from 2 Jul 2027 to 10 May 2027.
17 Jun 2024 Planned primary completion date changed from 2 Jul 2027 to 10 May 2027.
21 Nov 2023 Planned number of patients changed from 500 to 600.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com